| Patent application number | Description | Published |
|---|
| 20090181030 | USE OF A PREPARATION BASED ON AN ANTIBODY DIRECTED AGAINST A TUMOR-ASSOCIATED GLYCOSYLATION - The invention relates to the use of a preparation based on an antibody directed against a tumor-associated glycosylation for preparing a medicament for the prophylactic and/or therapeutic treatment for the reduction or inhibition, respectively, of the growth of tumor cells in a cancer patient, as well as to a pharmaceutical preparation containing an antibody directed against a tumor-associated glycosylation. Moreover, the invention relates to a preparation for pharmaceutical and/or diagnostic use, a diagnostic method and an agent for determining the risk of metastasis formation in a cancer patient, as well as a method of producing a preparation based on a body fluid or tissue, in each case using the antibody directed against a tumor-associated glycosylation. | 07-16-2009 |
| 20100233178 | USE OF ANTIBODIES FOR THE VACCINATION AGAINST CANCER - Described is the use of antibodies which are directed against human cellular membrane antigens for the vaccination against cancer diseases. | 09-16-2010 |
| 20100310551 | IMMUNOGENIC, MONOCLONAL ANTIBODY - The invention relates to an immunogenic antibody which comprises at least two different epitopes of a tumor-associated antigen. | 12-09-2010 |
| 20100316624 | TREATMENT OF FIBROSES AND LIVER DISORDERS - The present invention relates to ACE2 for the therapeutic treatment or prevention of a fibrosis or liver disorder. | 12-16-2010 |
| 20110020315 | TREATMENT OF INFLAMMATORY ILLNESSES WITH ACE2 - The present invention relates to ACE2 for the therapeutic treatment or prevention of inflammation. | 01-27-2011 |
| 20110020331 | N-GLYCOSYLATED ANTIBODY - The invention relates to a monoclonal antibody or derivative or fragment thereof that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region or region equivalent to the Fc region of said antibody or derivative or fragment thereof carries a bi-sected hybrid type N-glycosylation pattern and that said antibody shows at least 10 fold increased ADCC and at least 10% reduced CDC activity. | 01-27-2011 |
| 20110033524 | TREATMENT OF TUMORS - The invention provides for innovative improvements in tumour therapy, particularly therapies which are conducted using endogenous substances and which have no or only mild side-effects. Accordingly the present invention relates to methods of treating or preventing tumor diseases other than lung cancer comprising administering a polypeptide with an angiotensin-converting-enzyme-2 (ACE2) activity. | 02-10-2011 |
| 20120003232 | USE OF ANTIBODIES FOR THE VACCINATION AGAINST CANCER - Described is the use of antibodies which are directed against human cellular membrane antigens for the vaccination against cancer diseases. | 01-05-2012 |
